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1. INTRODUCTION {#mgg31355-sec-0005}
===============

Facial development occurs during the early days of intrauterine life by the formation of facial processes from the first pharyngeal arch and their subsequent fusion (Afshar, Brugmann, & Helms, [2012](#mgg31355-bib-0002){ref-type="ref"}). Derangement in this process results in orofacial clefts. Orofacial clefts are a group of congenital defects that are present with the discontinuity of the affected part of the face, which can either occur in isolation (non‐syndromic), or together with other defects (syndromic), with a preponderance of the former (Gatta et al., [2004](#mgg31355-bib-0008){ref-type="ref"}). Van der Woude syndrome (VWS) (OMIM: 119300 and 606713), an autosomal dominant disorder with variable expression and a high level of penetrance (Lam, David, Townsend, & Anderson, [2010](#mgg31355-bib-0013){ref-type="ref"}), is the most common syndromic cleft accounting for 2% of all cases (Murray et al., [1997](#mgg31355-bib-0018){ref-type="ref"}) It classically presents with lip pits and either cleft lip, cleft lip/palate, or cleft palate only. (Kondo et al., [2002](#mgg31355-bib-0035){ref-type="ref"}; Malik, Wilcox, & Naz, [2013](#mgg31355-bib-0017){ref-type="ref"}; Van Der Woude, [1954](#mgg31355-bib-0025){ref-type="ref"}).

Mutations in the Interferon Regulatory Factor Six (*IRF6*) (OMIM: 607199) (Kondo et al., [2002](#mgg31355-bib-0035){ref-type="ref"}; Ural, Bilgen, Çakmakli, & Bekerecioğlu, [2019](#mgg31355-bib-0023){ref-type="ref"}), and Grainy Head Like Three (*GRHL3*) (OMIM: 608317) (Peyrard‐Janvid et al., [2014](#mgg31355-bib-0019){ref-type="ref"}) genes have been shown to cause VWS and Popliteal pterygium syndrome (PPS) (OMIM: 119500). *IRF6* is the only member of the *IRF* gene family involved in the craniofacial development (Starink et al., [2017](#mgg31355-bib-0022){ref-type="ref"}). It is a protein‐coding gene with a highly conserved N terminal DNA‐binding domain and a less conserved C terminal protein‐binding domain (Ben, Jabs, & Chong, [2005](#mgg31355-bib-0031){ref-type="ref"}; Kondo et al., [2002](#mgg31355-bib-0035){ref-type="ref"}). Non‐ random mutations in the coding regions of *IRF6* account for 70% of cases of VWS with the majority of these mutations located at the DNA‐binding domain (exon 3, 4) and the protein‐binding domain (exon 7--9) (Ferreira de Lima et al., [2009](#mgg31355-bib-0007){ref-type="ref"}).

There are several bioinformatics tools used to predict the pathogenicity of genetic mutations (Adzhubei et al., [2010](#mgg31355-bib-0001){ref-type="ref"}; Kumar, Henikoff, & Ng, [2009](#mgg31355-bib-0012){ref-type="ref"}; Venselaar, Te Beek, Kuipers, Hekkelman, & Vriend, [2010](#mgg31355-bib-0039){ref-type="ref"}) including SIFT, Polyphen and HOPE. However, the conflicting results from existing bioinformatics tools (Hicks, Wheeler, Plon, & Kimmel, [2011](#mgg31355-bib-0009){ref-type="ref"}), the paucity of the functional data on reported variants, as well as the need for a more robust tool to accurately predict the clinical implications of these variants led to the development of the Combined Annotation Dependent Depletion score (CADD score, Kircher et al. [2014](#mgg31355-bib-0034){ref-type="ref"}).

CADD is a comprehensive prediction tool developed by Kircher, Jain, O'Roak, Cooper, and Shendure ([2014](#mgg31355-bib-0011){ref-type="ref"}). It merges the algorithms of over 60 other previously developed tools to produce a single result. It thus compensates for the loopholes of the other individual tools and allowing for a more accurate prediction of the pathogenicity of these mutations. This is achieved via a scoring system linked to existing genomic databases using a score of 20 for the top 1% and 30 for the top 0.1% of the most deleterious genetic mutations in the human genome (Kircher et al., [2014](#mgg31355-bib-0011){ref-type="ref"}).

The current study reviewed the literature to update the list of *IRF6* variants reported for VWS, predicted their clinical significance using the CADD score, and reported novel *IRF6* variants identified in Africans and Puerto Ricans with VWS.

2. METHODOLOGY {#mgg31355-sec-0006}
==============

2.1. Literature search {#mgg31355-sec-0007}
----------------------

We used PubMed with the search terms: \"Van der Woude syndrome and Popliteal pterygium syndrome,\" \"IRF6,\" and \"Orofacial cleft\" to identify studies that reported novel mutation(s) not found in the Leslie et al. ([2013](#mgg31355-bib-0015){ref-type="ref"}) study. We also compiled the CADD score for all the reported mutations using the CADD single nucleotide variant (SNV) look‐up feature (GRCh37‐v1.4 version).

2.2. New study population and sample information {#mgg31355-sec-0008}
------------------------------------------------

### 2.2.1. Ethical compliance {#mgg31355-sec-0009}

The new study populations include Nigerians, Ghanaians, Ethiopians, and Puerto‐Ricans. Ethical approval for this project was received from the Institutional Review Boards (IRBs) at the University of Iowa (Iowa approvals numbers: 201101720), Lagos University Teaching Hospital Idi‐Araba, Lagos (IRB approval number: ADM/DCST/HREC/VOL.XV/321), Obafemi Awolowo University Teaching Hospital Ile‐Ife (IRB approval number: ERC/2011/12/01), Kwame Nkrumah University of Science and Technology (IRB approval number: CHRPE/RC/018/13), the Addis Ababa University (IRB approval number: 003/10/surg), the University of Puerto‐Rico (IRB approval number: 0640111), and Kwazulu‐Natal University (IRB approval number: BE309/18).

2.3. DNA sequencing {#mgg31355-sec-0010}
-------------------

Primer sequences that were used to amplify exons 1 to 9 of *IRF6* (RefSeq NM_006147.4) have been previously published (Ferreira Butali et al., [2014](#mgg31355-bib-0005){ref-type="ref"}; de Lima et al., [2009](#mgg31355-bib-0007){ref-type="ref"}) and available on request. All DNA processing protocols, PCR conditions, and electrophoretic procedures are available at the Murray laboratory website (<http://genetics.uiowa.edu/protocols.php>). The amplified DNA products were sent to Functional Biosciences in Madison, Wisconsin for sequencing using an ABI 3730XL DNA Sequencer. The sequence data and variants were viewed with CONSED. Each variant and genomic location that was revealed by CONSED were confirmed using the "Blat" function of THE UCSC Genome Browser. The functional consequences of variants were predicted using CADD, SIFT, and Polyphen‐2 to determine pathogenic and benign variants. HOPE was used to create a simulation of the mutant protein structure. The effect of a variant on mRNA splicing was ascertained using Human Splicing Finder 3.0 (<http://www.umd.be/HSF3/>). Furthermore, the effect of a variant on a regulatory region was predicted, using RegulomeDB (<http://regulomedb.org/>).

The Minor Allele Frequencies or the novelty of a variant was ascertained by comparing it to variants in the 1000 Genomes (<http://browser.1000genomes.org/index.html>), Exome Variant Server (<http://evs.gs.washington.edu/EVS/>), dbSNP ([www.ncbi.nlm.nih.gov/SNP/](http://www.ncbi.nlm.nih.gov/SNP/)) ExAC Browser (<http://exac.broadinstitute.org/>) and gnomAD (<https://gnomad.broadinstitute.org/>). If a variant has never been reported before in the literature or these databases, it was categorized as "novel." When a variant of interest was found in a proband, the samples from their parents were sequenced. Identified variants were confirmed by sequencing in the reverse direction. The presence or absence of the mutation in the parent\'s DNA was used to determine if such variation was "de novo" or segregated in the family.

The data that support the findings of this study are openly available in \[repository name e.g., "figshare"\] at http://doi.org/\[doi\], reference number \[reference number\].

3. RESULTS {#mgg31355-sec-0011}
==========

Following our literature search for variants reported after the Leslie et al. ([2013](#mgg31355-bib-0015){ref-type="ref"}) study, we identified 21 new mutations from nine papers and compiled a CADD score for them (Table [1](#mgg31355-tbl-0001){ref-type="table"}, Table [S1](#mgg31355-sup-0001){ref-type="supplementary-material"}). The majority (69) of these mutations were in exon 4 with 194 mutations having CADD scores in the 20s and 30s (Table [1](#mgg31355-tbl-0001){ref-type="table"}, Figure [1](#mgg31355-fig-0001){ref-type="fig"}). There were 13 nonsense mutations with scores of 40+. A nonsense mutation in exon 8 was discovered in a patient with PPS and was predicted to be a dominant‐negative mutation with a CADD score of 54 (Table [1](#mgg31355-tbl-0001){ref-type="table"}). These high CADD scores rank *IRF6* mutations among the top 0.1 to 0.0001% most deleterious mutations in the human genome.

###### 

Showing the reported *IRF6* mutations from 2013 till date

  Exon                            cDNAPos     Mutation                        Nucleotide change   Mutation type   CADD score   Population   References
  ------------------------------- ----------- ------------------------------- ------------------- --------------- ------------ ------------ ----------------------------------------------------------------
  3                               77          p\. Leu26Pro                    T \> C              missense        32           1            Sunny et al. ([2019](#mgg31355-bib-0037){ref-type="ref"})
  7                               720         c.720del c                      c.720del c          frameshift      16.53        1            Ural et al. ([2019](#mgg31355-bib-0023){ref-type="ref"})
  4                               294         p\. Asp98Glu                    T \> G              missense        22.9         1            Wang et al. ([2019](#mgg31355-bib-0040){ref-type="ref"})
  8                               1138        p.Pro380Ser                     C \> T              missense        29.6         1            Wang et al. ([2019](#mgg31355-bib-0040){ref-type="ref"})
  chr1:209.872.038--210.246.107               chr1:209.872.038--210.246.107                       Microdeletion   *N*/A        1            Mbuyi‐Musanzayi, ([2019](#mgg31355-bib-0036){ref-type="ref"})
  4                               254         C85F                            C \> T              Missense        25.8         1            Leslie et al. ([2016](#mgg31355-bib-0014){ref-type="ref"})
  7                               1060+1                                                          Splice site     *N*/A        1            
  4                               c.165delC   p.Ile56phefs\*7                                     Indels          *N*/A        1            
  4                               c.379delG   p.Gly127valfs\*43                                   indels          *N*/A        1            
  4                               175‐2                                       A \> C              Splice site     33           1            Gowans, [2017](#mgg31355-bib-0032){ref-type="ref"}
  4                               194         p.Gly65Val                      G \> T              Missense        26.2         1            
  4                               205         p.Glu69Lys                      G \> A              Missense        32           2            
  4                               379+1                                       G \> T              Splice site     34           1            
  6                               554         p.Asp185Thr                     A \> C              Missense        21.7         1            
  7                               960         p.Lys320Asp                     G \> C              Missense        25.7         1            
  3                               113         p.Iso38Thr                      T \> C              Missense        27.8         1            Tan et al, [2008](#mgg31355-bib-0038){ref-type="ref"}
  4                               196         p.Lys66X                        A \> T              Nonsense        38           1            Butali et al., [2014](#mgg31355-bib-0005){ref-type="ref"}
  4                               551         p.Pro126Pro                     T \> A              Splice site     N/A          2            
  7                               690         p.PheF230Leu                    T \> G              Missense        23.8         5            
  8                               1139        Pro380Gln                       C \> A              Missense        28.5         1            Khandelwal et al, ([2017](#mgg31355-bib-0033){ref-type="ref"})
  5                               673         Asp225His                       G \> C              Missense        32           1            
  3                               107         p.Phe36Tyr                      T \> A              Missense        29.3         1            This study
  4                               326         p.Lys109Thr                     A \> C              Missense        23.6         1            This study
  9                               1313        p.Gln438Leu                     A \> T              Missense        25.5         1            This study

\[Correction added on 17 July 2020, after first online publication: in Table 1, the last 2 mutation details under 'Mutation' column have been changed from 'p.Pro109Thr' to 'p.Lys109Thr' and 'p.Glu438Leu' to 'p.GLn109Thr', respectively.\]

John Wiley & Sons, Ltd

![Box plot showing higher Combined Annotation Dependent Depletion score in the protein binding domain (exon 3 and 4) compared to the DNA binding domain (exon 7--9) of IRF6](MGG3-8-e1355-g001){#mgg31355-fig-0001}

In the current study, we identified five mutations, three novel missense mutations: p.Phe36Tyr, p.Lys109Thr, p.Gln438Leu, and two previously reported nonsense mutations: p.Ser424\*and p.Arg250\*. The three missense mutations were predicted to be probably damaging/ damaging by Polyphen‐2 and Sift prediction tools. The p.Phe36Tyr mutation located in exon 3 was identified in family A where both mother and child had shallow lip pits characteristic of VWS with an unaffected father (Figure [2](#mgg31355-fig-0002){ref-type="fig"}). The p.Lys109Thr mutation located in exon 4 was identified in family B where samples for both parents were not available but were absent in the maternal grandmother. Thus, we were unable to determine the mode of inheritance. The proband with p.Gln438Leu mutation in exon 9, identified in family C, had incomplete cleft lip without lip pits and both parents appear clinically unaffected. The known nonsense mutations were in exon 9 and 7, respectively. The missense mutations (p.Phe36Tyr, p.Lys109Thr and p.Gln438Leu) had CADD scores 29, 23.6, and 25.5, while the nonsense mutations (p. Ser424\* and p. Arg250\*) had CADD scores of 40 and 43, respectively, as shown in (Table [2](#mgg31355-tbl-0002){ref-type="table"}). The data that support the findings of this study are openly available in ClinVar at <https://submit.ncbi.nlm.nih.gov/clinvar/>, submission ID \[SUB7353596\].

![Showing the structural changes for the amino acid change p. Phe36Tyr (a), p. Gln438Leu (b) and p. Lys109thr (c) \[Correction added on 22 July 2020, after first online publication: in Figure 2 caption, the order of the legends (b) and (c) has been interchanged so it reads 'p. Gln438Leu (b) and p. Lys109thr (c)'.\]](MGG3-8-e1355-g002){#mgg31355-fig-0002}

###### 

Showing the distribution of CADD score per exon

  CADD score   Exon 3   Exon 4   Exon 5   Exon 6   Exon 7   EXON 8   Exon 9
  ------------ -------- -------- -------- -------- -------- -------- --------
  10--20       1                                   1                 
  20--30       23       43       1        4        17       7        10
  30--40       20       24       1        4        23       7        7
  40--50                2        1        2        6        3        3
  \>50                                                      1        

John Wiley & Sons, Ltd

4. DISCUSSION {#mgg31355-sec-0012}
=============

Non‐random mutations in the *IRF6* highly conserved DNA‐binding domain (exon 3 and 4) and the less conserved protein‐binding domain (exon 7--9) have been implicated in the etiology of VWS and PPS (Ferreira de Lima et al., [2009](#mgg31355-bib-0007){ref-type="ref"}). In this study, we found five *IRF6* mutations after sequencing VWS families from Africa and Puerto Rico. These include p.Phe36Tyr, p.Lys109Thr, p.Ser424\*, p.Arg250\*, and p.Gln438Leu. The missense mutation (p.Phe36Tyr), identified in a Puerto Rican family segregates in the family (proband and mother) and confirms a maternal mode of inheritance. Based on the HOPE analyses, we observed that the mutant is in a domain that is important for the binding of other protein molecules. The mutant is large and will not fit into the core of the IRF6 protein where the wild type resides. Also, the wild‐type residue is more hydrophobic and thus the mutant might disturb the interaction between domains and thereby affect the function of the protein. The p.Lys109thr mutant is smaller compared to the wild type leading to an empty space in the core of the protein. Furthermore, the wild type is more hydrophobic and positively charge allowing it to form a salt bridge with aspartic acid at position 98, which is required for proper protein folding. Replacing it with a neutral and less hydrophobic mutant residue will distort the protein folding and also affect its ability to interact with other molecules---an important function of the domain. The mutant residue for the p.Gln438Leu is smaller and less hydrophobic, thus, affecting the interaction with other residues within the domain as well as the binding capacity of the domain. Unlike the previous two mutations where the wild type residue is highly conserved at their respective positions, the wild type is not conserved at this amino acid position (438). However, the mutant residue was also not among the residue types that have been observed at this position. Thus, why it was predicted as damaging to the protein by Sift and Polyphen‐2 would require further study, perhaps using zebrafish or a cell‐based assay as previously reported for other variants (Li et al., [2017](#mgg31355-bib-0016){ref-type="ref"}).

When we reviewed the family data for the proband with the p.Phe36Tyr mutation, we observed that VWS was present in the mother. A family history of different types of clefts, the presence of lower lip pits, and types of cancer such as breast and colon cancer were found on the maternal side of the family. *IRF6* has shown tumor‐suppressor activities in different cancer types (Botti et al., [2011](#mgg31355-bib-0004){ref-type="ref"}) suggesting a possible connection. Other families did not provide access to the parental data so we were unable to ascertain the pattern of inheritance or the possibility of a de novo *mutation*.

A recent study functionally tested some *IRF6* variants in zebrafish embryo and did not find any correlation between the Polyphen‐2 and SIFT prediction and functional consequences in zebrafish embryos (Li et al., [2017](#mgg31355-bib-0016){ref-type="ref"}). However, when we reviewed the CADD score for the variants with functional consequences in zebrafish from the Li et al. ([2017](#mgg31355-bib-0016){ref-type="ref"}) study, we observed that over 95% of the variants had CADD scores \>25 . This observation further buttresses the relationship between high CADD score and the likelihood of pathogenicity (van der Velde et al., [2017](#mgg31355-bib-0024){ref-type="ref"}) . However, caution should be exercised so as not to use CADD score alone to assign pathogenicity and efforts should be made to follow the guidelines set by the American College of Medical Genetics and Genomics (ACMGG) for assigning pathogenicity to sequence variants (Richards et al., [2015](#mgg31355-bib-0020){ref-type="ref"}). The previous work by De Lima et al. ([2009](#mgg31355-bib-0007){ref-type="ref"}) and Leslie et al. ([2013](#mgg31355-bib-0015){ref-type="ref"}) showed the distribution of mutations in *IRF6* to be non‐random, segregating primarily in the DNA‐binding (exon 3 and 4), and protein‐binding domains (exon 7--9). Since most of these mutations were in exon 4, thus they proposed a major function for the DNA‐binding domain in the activities of *IRF6*. However, when 30 missense mutations (16 in the DNA‐binding domain and 14 in the protein‐binding domain) of *IRF6* were isolated in patients with VWS and PPS were functionally tested in zebrafish embryos, 50% (15) were shown to be pathogenic. Most (11) of the pathogenic variants in zebrafish were in the protein‐binding domain (exons 7--9). Furthermore, we observed a higher rate of nonsense mutations with very high CADD scores in the protein‐coding domain which are pathogenic. Finally, we also observed that the mutation that resulted in G/C in the DNA‐binding domain and A/T in the protein‐binding domain tends to be more common among the variants that induced rupture (pathogenic) in the Li et al. ([2017](#mgg31355-bib-0016){ref-type="ref"}) study.

5. CONCLUSION {#mgg31355-sec-0013}
=============

In conclusion, findings from the current study provided additional information on VWS mutations which is important for diagnostic and counseling purposes especially for families with a previous history.
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